Brian Carley Sells 5,000 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Brian Carley sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director owned 27,825 shares in the company, valued at approximately $16,935,129.75. The trade was a 15.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Price Performance

MEDP stock traded up $8.11 during trading on Friday, hitting $620.75. 225,439 shares of the stock traded hands, compared to its average volume of 347,887. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm’s 50 day moving average is $547.09 and its two-hundred day moving average is $491.80. The stock has a market cap of $17.33 billion, a price-to-earnings ratio of 36.39, a price-to-earnings-growth ratio of 2.71 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the topic of several analyst reports. TD Cowen upped their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Barclays set a $600.00 target price on Medpace in a report on Thursday, July 23rd. Robert W. Baird upped their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Finally, BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $584.18.

Institutional Investors Weigh In On Medpace

A number of large investors have recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. purchased a new stake in Medpace during the 2nd quarter valued at $27,000. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new stake in shares of Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp bought a new stake in shares of Medpace in the second quarter worth $30,000. Finally, Allied Private Wealth LLC purchased a new stake in Medpace during the second quarter valued at $31,000. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.